374 related articles for article (PubMed ID: 31238897)
1. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.
Skaga E; Kulesskiy E; Brynjulvsen M; Sandberg CJ; Potdar S; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
Clin Transl Med; 2019 Dec; 8(1):33. PubMed ID: 31889236
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
6. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
[TBL] [Abstract][Full Text] [Related]
7. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
8. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
Hothi P; Martins TJ; Chen L; Deleyrolle L; Yoon JG; Reynolds B; Foltz G
Oncotarget; 2012 Oct; 3(10):1124-36. PubMed ID: 23165409
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
10. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
11. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data.
Cheng HW; Liang YH; Kuo YL; Chuu CP; Lin CY; Lee MH; Wu AT; Yeh CT; Chen EI; Whang-Peng J; Su CL; Huang CY
Cell Death Dis; 2015 May; 6(5):e1753. PubMed ID: 25950483
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
13. Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells.
Spina R; Voss DM; Asnaghi L; Sloan A; Bar EE
J Vis Exp; 2018 Jan; (131):. PubMed ID: 29364250
[TBL] [Abstract][Full Text] [Related]
14. High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
Yu KK; Taylor JT; Pathmanaban ON; Youshani AS; Beyit D; Dutko-Gwozdz J; Benson R; Griffiths G; Peers I; Cueppens P; Telfer BA; Williams KJ; McBain C; Kamaly-Asl ID; Bigger BW
PLoS One; 2018; 13(3):e0193694. PubMed ID: 29499065
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
16. In vitro demonstration of salinomycin as a novel chemotherapeutic agent for the treatment of SOX2‑positive glioblastoma cancer stem cells.
Magrath JW; Raney WR; Kim Y
Oncol Rep; 2020 Aug; 44(2):777-785. PubMed ID: 32627023
[TBL] [Abstract][Full Text] [Related]
17. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ
Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873
[TBL] [Abstract][Full Text] [Related]
18. An in silico screen links gene expression signatures to drug response in glioblastoma stem cells.
Riddick G; Song H; Holbeck SL; Kopp W; Walling J; Ahn S; Zhang W; Fine HA
Pharmacogenomics J; 2015 Aug; 15(4):347-53. PubMed ID: 25446780
[TBL] [Abstract][Full Text] [Related]
19. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
